Gap19: Selective Connexin 43 Hemichannel Blocker for Neuroprotection & Immune Modulation

Executive Summary: Gap19 is a peptide inhibitor that selectively blocks connexin 43 (Cx43) hemichannels without affecting gap junction channels, enabling targeted modulation of neuroglial interactions (APExBIO). It has an in vitro IC50 of approximately 50 μM for Cx43 hemichannels and 142 μM for ATP release inhibition in cultured cortical astrocytes (Wu et al. 2020). In vivo, Gap19 reduces infarct volume and neurological deficits in mouse models of middle cerebral artery occlusion when administered intracerebroventricularly at 300 μg/kg. The TAT-conjugated form is effective intraperitoneally at 25 mg/kg post-reperfusion, implicating the JAK2/STAT3 pathway. Gap19’s solid physical form, water solubility (≥58.07 mg/mL), and stability at -20°C facilitate reliable laboratory workflows (APExBIO).

Biological Rationale

Connexin 43 (Cx43) forms both hemichannels and gap junction channels, mediating cell-cell communication in astrocytes, neurons, and immune cells. Cx43 hemichannels enable ATP and metabolite release during physiological and pathological signaling (Wu et al. 2020). Aberrant hemichannel opening is implicated in neuroinflammation, ischemia/reperfusion injury, and immune cell polarization. Selective inhibition of Cx43 hemichannels, without disturbing gap junctions, offers a precise approach to dissecting neuroglial and immune crosstalk while preserving essential intercellular coupling. Gap19, a peptide derived from the Cx43 intracellular cytoplasmic loop, is engineered to achieve this selectivity, providing a tool for targeting disease-relevant signaling in stroke, neuroprotection, and immune modulation (APExBIO).

Mechanism of Action of Gap19

Gap19 is a short peptide (C55H96N14O13, MW 1161.45) corresponding to a segment of the Cx43 intracellular cytoplasmic loop. It binds to Cx43 hemichannels and prevents their pathological opening, blocking channel-mediated ATP release and downstream signaling. Gap19 does not affect gap junction channel communication, as validated by dual patch-clamp and dye-transfer assays (Wu et al. 2020). In astrocytes, Gap19 inhibits ATP release in a dose-dependent manner (IC50 = 142 μM), modulating neuroglial signaling. In immune cells, such as RAW264.7 macrophages, Gap19 suppresses M1-type polarization by inhibiting the Cx43/NF-κB pathway, as evidenced by decreased expression of iNOS, TNF-α, IL-1β, and CD86 upon treatment (Wu et al. 2020).

Evidence & Benchmarks

• Gap19 selectively blocks Cx43 hemichannels with an IC50 of ~50 μM and does not inhibit gap junction channels (Wu et al. 2020, https://doi.org/10.3892/mmr.2020.11023).
• In primary astrocyte cultures, Gap19 inhibits ATP release in a dose-dependent manner (IC50 = 142 μM), reducing neuroinflammatory signaling (Wu et al. 2020).
• In a mouse model of middle cerebral artery occlusion, intracerebroventricular administration of Gap19 (300 μg/kg) decreases infarct volume and improves neurological scores (APExBIO).
• TAT-Gap19 (25 mg/kg, intraperitoneal, 4h post-reperfusion) confers neuroprotection, with evidence implicating JAK2/STAT3 pathway modulation (APExBIO).
• Gap19 and the Cx43/NF-κB axis are central to restraining M1-type macrophage polarization, supporting its utility in immune modulation studies (Wu et al. 2020, https://doi.org/10.3892/mmr.2020.11023).

For a broader context on translational applications and pathway insights, see Gap19: Redefining Selective Connexin 43 Hemichannel Inhibition (extends on immune and neuroglial crosstalk), Gap19: Selective Connexin 43 Hemichannel Blocker for Neuroinflammation (focuses on pathway dissection), and Gap19: Cx43 Hemichannel Inhibitor Peptide for Dissecting Neuroglial Signaling (details robust solubility and workflow integration). This article updates these resources by directly benchmarking peer-reviewed quantitative data and product specifications.

Applications, Limits & Misconceptions

• Neuroprotection in Ischemia and Stroke: Gap19 reduces infarct size and neurological deficits when administered post-ischemia (APExBIO).
• Immune Modulation: Gap19 inhibits RAW264.7 macrophage polarization to the pro-inflammatory M1 phenotype by suppressing the Cx43/NF-κB signaling axis (Wu et al. 2020).
• Neuroglial Interaction Studies: Gap19 allows precise dissection of Cx43 hemichannel-dependent signaling without disrupting gap junction-mediated coupling.
• JAK2/STAT3 Pathway Research: TAT-Gap19 implicates JAK2/STAT3 modulation in neuroprotection (APExBIO).

Common Pitfalls or Misconceptions

• Gap19 does not block Cx43 gap junction channels; its action is hemichannel-selective (Wu et al. 2020).
• Gap19 is ineffective for hemichannels formed by connexins other than Cx43.
• Gap19 solutions are for short-term use only; long-term storage in solution may degrade activity (APExBIO).
• It is insoluble in ethanol and must be dissolved in water or DMSO.
• Systemic effects in vivo require appropriate peptide conjugation (e.g., TAT) for blood-brain barrier penetration.

Workflow Integration & Parameters

Gap19 (SKU: B4919) is supplied as a solid, with a molecular weight of 1161.45 (C55H96N14O13). It is readily soluble in water (≥58.07 mg/mL) and DMSO (≥26.55 mg/mL), but not in ethanol. For optimal stability, store at -20°C and prepare solutions fresh or use within a short timeframe. In vitro, effective concentrations for Cx43 hemichannel inhibition range from 10–200 μM, with 50 μM sufficient for most channel-blocking studies. For in vivo protocols, intracerebroventricular administration at 300 μg/kg or TAT-Gap19 intraperitoneally at 25 mg/kg (administered 4 hours post-reperfusion in stroke models) are benchmarked dosing regimens (APExBIO). Detailed protocols and batch-specific quality data are available from APExBIO.

Conclusion & Outlook

Gap19 has established itself as a gold-standard tool for selective Cx43 hemichannel inhibition in neuroscience and immunology. Its unique selectivity, robust solubility, and translationally validated neuroprotective effects position it at the forefront of stroke, neuroinflammation, and immune polarization research. Ongoing studies continue to clarify its pathway-specific effects and expand its utility to broader disease models. For advanced application insights and pathway-focused protocol design, consult APExBIO and related literature.